Objective:To investigate of effect of cinacalcet on anemia parameters, left ventricular mass index and parathyroid volume in patients with severe secondary hyperparathyroidism treated by hemodialysis.Methods:A total of 76 maintenance hemodialysis patients with severe secondary hyperparathyroidism treated in the Third People's Hospital of Yunnan Province from January 2018 to December 2019 were selected. Laboratory parameters, total parathyroid volume (TPV), left ventricular mass index (LVMI), dosage of erythropoietin (EPO) and sevelamm carbonate were recorded at baseline and each follow-up point. After 12 months of cinacalcet treatment, the patients were divided into decreased group(55 cases) and increased group(21 cases) according to the change of total parathyroid volume. The clinical characteristics of the two groups were compared.Results:After 6 and 12 months of cinacalcet treatment, hemoglobin (Hb), hematocrit (Hct) and reticulocyte percentage (Ret) were significantly higher than those at baseline(all P<0.001). Parathyroid hormone (PTH) was significantly decreased after 6 and 12 months of cinacalcet treatment ( P<0.05). Left ventricular mass index (LVMI) decreased after 12 months of cinacalcet treatment, but the difference was not statistically significant ( P>0.05). Fibroblast growth factor 23 (FGF23) and total parathyroid volume were significantly lower than baseline levels after 12 months of cinacalcet treatment (all P<0.05). The dosage of EPO decreased significantly after 6 and 12 months of cinacalcet treatment ( P<0.05). The final total parathyroid volume of the decreased parathyroid volume group and the increased parathyroid volume group were (3.72±1.02) cm 3 and (6.11±0.99) cm 3, respectively, and the difference was statistically significant ( P<0.05). The final iPTH of the two groups decreased significantly, but the difference was not statistically significant ( P>0.05). Conclusions:Cinacalcet in the treatment of severe secondary hyperparathyroidism in hemodialysis patients can improve anemia parameters, reduce EPO dosage and parathyroid volume. Improvement in LVMI may be beneficial, but a larger sample and longer observation time are needed to determine.

目的 总结经额入路神经内镜治疗高血压基底核区脑出血的疗效.方法 回顾性分析60例高血压基底核区脑出血病例资料,其中传统开颅手术组30例,神经内镜手术组30例,两组病例术前临床资料差异无统计学意义(P>0.05).结果血肿清除率:神经内镜组高于传统开颅组,差异具统计学意义(P=0.0112);手术时间、术中失血量与住院时间:神经内镜组均少于传统开颅组,差异具统计学意义(P<0.05);术后1周GCS:神经内镜组高于传统开颅组,差异具统计学意义(P<0.05).结论 经额入路神经内镜治疗高血压基底核区脑出血更安全有效.